News stories about Opexa Therapeutics (NASDAQ:ACER) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Opexa Therapeutics earned a news impact score of 0.01 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.0199660410953 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Opexa Therapeutics (NASDAQ:ACER) opened at $17.42 on Wednesday. The firm has a market cap of $128.93, a price-to-earnings ratio of -4.32 and a beta of 2.23. Opexa Therapeutics has a 52 week low of $5.69 and a 52 week high of $22.63.

Opexa Therapeutics (NASDAQ:ACER) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter. analysts forecast that Opexa Therapeutics will post -1.48 EPS for the current fiscal year.

Several equities research analysts have issued reports on the stock. HC Wainwright set a $50.00 price objective on shares of Opexa Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 4th. ValuEngine downgraded shares of Opexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at

Opexa Therapeutics Company Profile

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with's FREE daily email newsletter.